Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

Summary

This is a placebo-controlled study evaluating the effects of rosiglitazone on functional brain activity and cognition in patients with mild to moderate Alzheimer's Disease (AD).

Timeline

Start

2004-05-18

Primary completion

2008-07-10

Completion

2008-07-10

Outcome

Missed primary endpoint

registry analysis (unspecified test); Placebo vs Rosiglitazone; p = 0.1695; Mean Difference (Net) 0.1334 (95% CI -0.0583 to 0.3251); Mixed model for repeated measures NCT00265148 ↗

Publications

• Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown AP, Zvartau-Hind M, Lotay N, Lai RY, Castiglia M, Jeter B, Matthews JC, Chen K, Bandy D, Reiman EM, Gold M, Rabiner EA, Matthews PM. A multi-center randomized proof-of-concept clinical trial applying [(1)(8)F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010;22(4):1241-56. doi: 10.3233/JAD-2010-100939.

Drugs

Indications